Roche Pharmaceutical Development and Sales Overview
Major granted approvals 2022
US
EU
China
Vabysmo (faricimab)
RG7716
DME
Jan 2022
RG7596
Polivy
1L DLBCL
May 2022
RG7446
Tecentriq
NSCLC adj
March 2022
RG1569
Vabysmo (faricimab)
RG7716
WAMD
RG7446
Tecentriq
NSCLC adj
RG1569
Actemra
RA SC
RG7716
Japan-Chugai
Actemra
COVID-19 pneumonia
Jan 2022
Vabysmo (faricimab)
DME
Jan 2022
June 2022
April 2022
Actemra
Lunsumio (mosunetuzumab)
Rozlytrek
March 2022
Vabysmo (faricimab)
RG1569
GCA IV
RG7828
3L+ FL
RG6268
NTRK+ solid tumors
RG7716
WAMD
Feb 2022
June 2022
July 2022
Evrysdi
Vabysmo (faricimab)
Rozlytrek
March 2022
Perjeta + Herceptin
RG7916
SMA presymptomatic pediatric <2mo
RG7716
May 2022
Xofluza
DME
Sept 2022
Vabysmo (faricimab)
RG6268
ROS1+ NSCLC
RG1273
Aug 2022
RG6152
influenza pediatric
Aug 2022
RG7716
WAMD
Sept 2022
RG7446
RG6013
RG105
RG7596
HER-2+ CRC
March 2022
Tecentriq
NSCLC adj
May 2022
Hemlibra
acquired Hemophilia A
June 2022
Rituxan
NMOSD
June 2022
Polivy
1L DLBCL
Aug 2022
Status as of October 18, 2022
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
Roche
58View entire presentation